SM
Sabby Management Portfolio holdings
AUM
$13M
This Quarter Return
-0.2%
1 Year Return
-26.95%
3 Year Return
-56.43%
5 Year Return
-61.92%
10 Year Return
-71.17%
AUM
$156M
AUM Growth
+$156M
(+7.2%)
Cap. Flow
-$4.09M
Cap. Flow
% of AUM
-2.63%
Top 10 Holdings %
Top 10 Hldgs %
70.68%
Holding
160
New
45
Increased
11
Reduced
31
Closed
38
Top Buys
| 1 |
Biogen
BIIB
|
$50.1M |
| 2 |
SPDR S&P 500 ETF Trust
SPY
|
$11.7M |
| 3 |
Cogent Biosciences
COGT
|
$9.38M |
| 4 |
Incyte
INCY
|
$6.82M |
| 5 |
Nektar Therapeutics
NKTR
|
$4.13M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$57.4M |
| 2 |
Esperion Therapeutics
ESPR
|
$8.92M |
| 3 |
SELLAS Life Sciences
SLS
|
$7.99M |
| 4 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
$5.7M |
| 5 |
InspireMD
NSPR
|
$4.25M |
Sector Composition
| 1 | Healthcare | 86.15% |
| 2 | Consumer Staples | 2.32% |
| 3 | Consumer Discretionary | 0.64% |
| 4 | Materials | 0.5% |
| 5 | Technology | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Biogen
BIIB
$19.4B
| $50.1M | 5.96% | +182,898 | New | +$50.1M |
|
|
ODT
2
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $15.6M | 1.85% | 734,272 -91,179 | -11% | -$1.93M |
|
|
3
SPDR S&P 500 ETF Trust
SPY
$658B
| $11.7M | 1.39% | +44,500 | New | +$11.7M |
|
|
4
Cogent Biosciences
COGT
$1.69B
| $9.38M | 1.12% | +843,850 | New | +$9.38M |
|
|
5
Incyte
INCY
$16.5B
| $6.82M | 0.81% | +81,861 | New | +$6.82M |
|
|
6
Nektar Therapeutics
NKTR
$568M
| $6.25M | 0.74% | 58,831 +38,831 | +194% | +$4.13M |
|
7
Arcadia Biosciences
RKDA
$5.28M
| $3.61M | 0.43% | +150,376 | New | +$3.61M |
|
8
Sangamo Therapeutics
SGMO
$157M
| $2.7M | 0.32% | +142,136 | New | +$2.7M |
|
9
Citius Pharmaceuticals
CTXR
$22.6M
| $1.99M | 0.24% | 641,201 +431,070 | +205% | +$1.34M |
|
10
Outlook Therapeutics
OTLK
$37.8M
| $1.88M | 0.22% | 2,108,249 +28,882 | +1% | +$25.7K |
|
|
CANF
11
Can-Fite BioPharma
CANF
$9.2M
| $1.77M | 0.21% | +1,228,091 | New | +$1.77M |
|
12
Soleno Therapeutics
SLNO
$3.6B
| $1.66M | 0.2% | 917,835 +2,735 | +0.3% | +$4.95K |
|
|
NOVN
13
DELISTED
Novan, Inc. Common Stock
NOVN
| $1.6M | 0.19% | +545,149 | New | +$1.6M |
|
|
QNRX
14
Quoin Pharmaceuticals
QNRX
$4.34M
| $1.56M | 0.19% | +243,980 | New | +$1.56M |
|
15
PAVmed
PAVM
$10.6M
| $1.49M | 0.18% | +908,817 | New | +$1.49M |
|
|
16
Bristol-Myers Squibb
BMY
$96B
| $1.47M | 0.18% | 23,312 -908,495 | -97% | -$57.4M |
|
17
Alnylam Pharmaceuticals
ALNY
$58.5B
| $1.37M | 0.16% | 11,500 -7,750 | -40% | -$923K |
|
|
18
Esperion Therapeutics
ESPR
$448M
| $1.36M | 0.16% | 18,823 -123,362 | -87% | -$8.92M |
|
19
Carisma Therapeutics
CARM
$8.98M
| $1.29M | 0.15% | +1,226,117 | New | +$1.29M |
|
20
Tempest Therapeutics
TPST
$44M
| $1.19M | 0.14% | 1,461,525 +861,525 | +144% | +$699K |
|
|
ZSAN
21
DELISTED
Zosano Pharma Corporation
ZSAN
| $1.18M | 0.14% | +233,779 | New | +$1.18M |
|
|
ARAV
22
DELISTED
Aravive, Inc. Common Stock
ARAV
| $1.16M | 0.14% | 702,364 -290,736 | -29% | -$480K |
|
23
Adverum Biotechnologies
ADVM
$64.6M
| $1.15M | 0.14% | 198,964 -101,036 | -34% | -$586K |
|
|
24
SELLAS Life Sciences
SLS
$202M
| $1.07M | 0.13% | 309,207 -2,314,403 | -88% | -$7.99M |
|
|
NURO
25
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
| $1M | 0.12% | 710,389 +530,350 | +295% | +$748K |
|